Charles Redwood
Overview
Explore the profile of Charles Redwood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Z, Sheehan A, Messer A, Tsui S, Sparrow A, Redwood C, et al.
Front Physiol
. 2024 Dec;
15:1489439.
PMID: 39735723
Introduction: Adrenergic activation of protein kinase A (PKA) in cardiac muscle targets the sarcolemma, sarcoplasmic reticulum, and contractile apparatus to increase contractile force and heart rate. In the thin filaments...
2.
Sequeira V, Wang L, Wijnker P, Kim K, Pinto J, Dos Remedios C, et al.
J Mol Cell Cardiol Plus
. 2023 May;
1():100007.
PMID: 37159677
Background: Hypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic disorder with patients typically showing heterozygous inheritance of a pathogenic variant in a gene encoding a contractile protein. Here, we study...
3.
Robinson P, Sparrow A, Psaras Y, Steeples V, Simon J, Broyles C, et al.
J Mol Cell Cardiol
. 2023 May;
180:44-57.
PMID: 37127261
We compared commonly used BAPTA-derived chemical Ca dyes (fura2, Fluo-4, and Rhod-2) with a newer genetically encoded indicator (R-GECO) in single cell models of the heart. We assessed their performance...
4.
Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy
Prondzynski M, Lemoine M, Zech A, Horvath A, Di Mauro V, Koivumaki J, et al.
EMBO Mol Med
. 2022 Aug;
14(8):e16423.
PMID: 35938313
No abstract available.
5.
Sontayananon N, Redwood C, Davies B, Gehmlich K
Biology (Basel)
. 2020 Nov;
9(11).
PMID: 33207727
Recent advances have made pluripotent stem cell (PSC)-derived cardiomyocytes an attractive option to model both normal and diseased cardiac function at the single-cell level. However, in vitro differentiation yields heterogeneous...
6.
Moreira L, Takawale A, Hulsurkar M, Menassa D, Antanaviciute A, Lahiri S, et al.
Nature
. 2020 Nov;
587(7834):460-465.
PMID: 33149301
Atrial fibrillation, the most common cardiac arrhythmia, is an important contributor to mortality and morbidity, and particularly to the risk of stroke in humans. Atrial-tissue fibrosis is a central pathophysiological...
7.
Robinson P, Sparrow A, Patel S, Malinowska M, Reilly S, Zhang Y, et al.
Am J Physiol Heart Circ Physiol
. 2020 Jul;
319(2):H306-H319.
PMID: 32618513
Dilated cardiomyopathy (DCM) is clinically characterized by dilated ventricular cavities and reduced ejection fraction, leading to heart failure and increased thromboembolic risk. Mutations in thin-filament regulatory proteins can cause DCM...
8.
Sparrow A, Watkins H, Daniels M, Redwood C, Robinson P
Am J Physiol Heart Circ Physiol
. 2020 Feb;
318(3):H715-H722.
PMID: 32083971
Thin filament hypertrophic cardiomyopathy (HCM) mutations increase myofilament Ca sensitivity and alter Ca handling and buffering. The myosin inhibitor mavacamten reverses the increased contractility caused by HCM thick filament mutations,...
9.
Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy
Prondzynski M, Lemoine M, Zech A, Horvath A, Di Mauro V, Koivumaki J, et al.
EMBO Mol Med
. 2019 Nov;
11(12):e11115.
PMID: 31680489
Hypertrophic cardiomyopathy (HCM) is a cardiac genetic disease accompanied by structural and contractile alterations. We identified a rare c.740C>T (p.T247M) mutation in ACTN2, encoding α-actinin 2 in a HCM patient,...
10.
Kresin N, Stucker S, Kramer E, Flenner F, Mearini G, Munch J, et al.
Front Physiol
. 2019 Apr;
10:239.
PMID: 30984009
No abstract available.